Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications.

Julie-Anne Tanner Lisa C Brown Kunbo Yu James LiBryan M Dechairo

Published in: ClinicoEconomics and outcomes research : CEOR (2019)

Antidepressant and antipsychotic prescribing that was congruent with combinatorial pharmacogenomic test guidance was associated with significant cost savings on Canadian prescription medications according to the Ontario Drug Benefit Formulary.

Keyphrases

adverse drug
clinical decision support
primary care
major depressive disorder
mental health
electronic health record
drug induced